- $13.72m
- $40.07m
- $3.00m
Annual cashflow statement for PAVmed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -35.9 | -56.1 | -103 | -79.3 | 28.4 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 13.9 | 16.9 | 30.5 | 22.7 | -63.7 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.083 | -1.57 | -0.716 | 1.59 | 0.512 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -21.9 | -40.6 | -71 | -52 | -33.6 |
| Capital Expenditures | -0.055 | -1.47 | -1.54 | -0.242 | -0.055 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -2.25 | -3.2 | 1 | -16.1 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale of Intangible Assets | |||||
| Cash from Investing Activities | -0.055 | -3.72 | -4.74 | 0.758 | -16.2 |
| Financing Cash Flow Items | -0.1 | -1.31 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 33 | 104 | 38.2 | 31.2 | 31.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11 | 60 | -37.5 | -20.1 | -18.5 |